Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Kamada Ltd. (KMDA)

6.01   0.14 (2.39%) 02-25 16:00
Open: 6.02 Pre. Close: 5.87
High: 6.23 Low: 5.73
Volume: 78,450 Market Cap: 279M
Kamada Ltd is an orphan drug, plasma-derived protein therapeutics company and develops & produces specialty plasma-derived protein therapeutics. Its flagship product include Glassia.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 6.233 - 6.264 6.264 - 6.295
Low: 5.662 - 5.692 5.692 - 5.722
Close: 5.96 - 6.009 6.009 - 6.059

Technical analysis

as of: 2020-02-25 4:31:05 PM
Overall:       
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 7.70     One year: 8.41
Support: Support1: 5.60    Support2: 4.66
Resistance: Resistance1: 6.59    Resistance2: 7.20
Pivot: 6.50
Moving Average: MA(5): 6.04     MA(20): 6.50
MA(100): 6.26     MA(250): 5.90
MACD: MACD(12,26): -0.18     Signal(9): -0.09
Stochastic oscillator: %K(14,3): 16.96     %D(3): 13.05
RSI: RSI(14): 37.54
52-week: High: 8.00  Low: 4.91  Change(%): -2.4
Average Vol(K): 3-Month: 5887  10-Days: 6651

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
KMDA has closed above bottom band by 21.2%. Bollinger Bands are 67.1% wider than normal. The large width of the bands suggest high volatility as compared to KMDA's normal range. The bands have been in this wide range for 2 bars. This is a sign that the current trend might continue.

Headline News

2020-01-21
Kamada Announces US$25 Million Private Placement
Kamada has entered a purchase agreement with FIMI Opportunity Funds to purchase US$25 million of its ordinary shares in a private placement. The post Kamada Announces US$25 Million Private Placement appeared first on Investing News Network .

2019-11-26
The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 25.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amgen, Inc. (NASDAQ: AMGN ) Antares Pharma Inc (NASDAQ: ATRS ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Arvinas Inc (NASDAQ: ARVN ) (Guggenheim initiated coverage of stock with Buy rating and $50 price target) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) (announced achievement of enrollment target in a Phase 3 trial of drug to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy) Axsome Therapeutics Inc (NASDAQ: AXSM ) Beigene Ltd (NASDAQ: BGNE ) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) BIO-TECHNE Corp (NASDAQ: TECH ) BioNTech SE – ADR (NASDAQ: BNTX ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Cue Biopharma Inc (NASDAQ: CUE ) DexCom, Inc. (NASDAQ: DXCM ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Epizyme Inc (NASDAQ: EPZM ) ESSA Pharma Inc (NASDAQ: EPIX ) Flexion Therapeutics Inc (NASDAQ: FLXN ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Globus Medical Inc (NYSE: GMED ) Halozyme Therapeutics, Inc.

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency NA
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Tweet this page Share on Facebook
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  Nasdaq Global Select
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 44.52
Shares Float (M) 24.13
% Held by Insiders 23.33
% Held by Institutions 36.89
Shares Short (K) 13
Shares Short P. Month (K)

Stock Financials

EPS 0.870
Book Value (p.s.) 3.130
PEG Ratio 3.77
Profit Margin 24.16
Operating Margin 22.80
Return on Assets (ttm) 15.0
Return on Equity (ttm) 30.9
Qtrly Rev. Growth 120.8
Gross Profit (p.s.) 0.931
Sales Per Share
EBITDA (p.s.) 0.814
Qtrly Earnings Growth
Operating Cash Flow (M) 25.28
Levered Free Cash Flow (M) 10.48

Stock Valuations

P/E 6.91
P/E Growth Ratio 0.02
P/BV 1.92
P/S 1.65
P/CF 10.58

Dividends & Splits

Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Forward Dividend
Last Split Date
Last Split Ratio -1e+010
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2019 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.